shares of Eloxx Pharmaceuticals Inc (ELOX) on
Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid modulating drug candidates. The company is headquartered in Waltham, Massachusetts and currently employs 29 full-time employees. The firm is focused on developing ribonucleic acid (RNA)-modulating drug candidates, which are designed to be eukaryotic ribosomal selective glycosides (ERSG). The company is developing its drug candidates for treating rare and ultra-rare premature stop codon diseases. ELX-02 is its lead investigational drug product candidate. ELX-02 is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development for systemic administration for cystic fibrosis and cystinosis. Its preclinical candidate pool consists of a library of novel ERSG drug candidates identified based on read-through potential and cytoplasmic ribosomal selectivity.